Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia
about
Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusionsProfile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromesβ-thalassemia intermedia: a clinical perspectiveTreating iron overload in patients with non-transfusion-dependent thalassemiaMRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and PitfallsHydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.Beta-thalassaemia intermedia: evaluation of endocrine and bone complications.Novel approach to reactive oxygen species in nontransfusion-dependent thalassemiaApproaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasiroxPulmonary hypertension in well-transfused thalassemia major patientsWhen to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia.Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatmentEstimating tissue iron burden: current status and future prospects.Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.Management of the thalassemiasNon-transfusion-dependent thalassemias.Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsSildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertensionDeferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia.Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.β-Thalassemia Intermedia: A Bird's-Eye View.Hypercoagulability in β-thalassemia: a status quo.Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.Current approach to iron chelation in children.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Clinical pharmacology of deferasirox.Guidelines for diagnosis and management of Beta-thalassemia intermedia.Management of non-transfusion-dependent thalassemia: a practical guide.Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.Iron Homeostasis and Trypanosoma brucei Associated Immunopathogenicity Development: A Battle/Quest for Iron.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia.Morbidities in non-transfusion-dependent thalassemia.β-Thalassemia.Secondary haemochromatosis in a patient with thalassemia intermediaInvestigational drugs in phase I and phase II clinical trials for thalassemia.Evaluation of the Relationship Between Hb F Levels and Nucleated Red Blood Cells with Morbidity in Non Transfusion-Dependent Thalassemia Patients.Pulmonary hypertension in non-transfusion-dependent thalassemia: Correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron.
P2860
Q26765306-3B9EAA51-F1C7-4BC9-8692-4269AE05491EQ26771519-EC32F958-D847-41FD-9C30-404D02E57837Q26828512-C093790A-FAC8-4473-AC92-D45CE8A7A5DDQ27009463-C1AB96E3-328C-4B05-8B62-866C62983576Q28072173-D13258FD-6D9F-4182-838C-58C4F77F92BBQ33436115-3B330E73-2BE1-4A2F-BF8A-D022AE61BFEFQ33943025-36C26784-2A10-4FC7-915B-5D0F6CC8AB83Q33993973-786AB543-0619-4EB5-BFAC-77019EF5A223Q34516223-64F7AB15-5064-4E3F-A427-32297545CEBCQ34979478-33F6E696-AB2E-4A8F-A425-B4649FB058DEQ34999542-E83EF345-FAFA-490C-AF60-A7B1E1A2A54FQ35193628-423E0BDE-F61A-4B9F-9744-17094FDFB1ECQ35793545-21532457-9BB1-41F1-92F7-F84276D75E36Q35906193-0E36D51B-A2C3-4CEB-94E3-86C0DEBCFECEQ36524624-D956E2C9-35FE-40C7-B421-DCBF86697FEFQ36870253-6883BEC7-A31C-4001-9E6B-CD21491C6AFEQ36892558-FD6D5ED8-0455-487A-A7E3-73C384F8225EQ36974108-E8E1C824-7544-4BC4-A5A6-323603B4AB94Q37144856-B6B58526-4103-4256-A837-A36B5D7EEDC1Q37214539-6445FDAE-91A2-4A2D-B01A-F3FAF541D262Q37394992-0152F091-0452-4B75-9BE2-77FD6BC9216CQ37595987-590A26BA-0182-4E07-8E86-C1DB3E19BECAQ37718392-C443F26A-77F7-4FAE-940B-1B49D99A7B8DQ38059250-6D78AD8B-8E89-4A2A-BB71-68B4362D4463Q38148200-FD0C6A75-BE17-46BD-9D6D-58D5807E6DECQ38197269-AB8840CE-6EE7-4542-B9F2-A54A2024053CQ38219588-170D619E-2D89-49B1-839E-1A79402917F2Q38226394-DE2CB9AC-FC20-4C6C-8048-7F3C420A482CQ38253432-318EC8C3-8171-4C10-8E2C-13F79CB80332Q38254291-E91474DB-AC40-4BB0-982F-1A4A27A2C178Q38423854-C4ADD962-CF55-46E1-8E3E-1D9872C60863Q38532068-A473E458-58FC-4D40-A03C-50AEDBBA87D8Q38650293-E37F4345-F81A-40F5-A5F5-4251696A69FCQ38679795-AA66C660-6B55-48F3-AACD-3F5CB9FABBCFQ38836177-CB5AA087-6D5D-4DF9-878E-F09830F9FB7EQ38998151-220F7614-EF5C-4608-9EDF-9D818D5FE6A4Q39114227-FD6E60FB-7BF6-4D72-8B76-49A88D2E5231Q39328286-04A2E472-C2D8-43EA-9191-8B30C66B780EQ40742219-BA972913-7F66-4232-8A83-83BCE96E96B3Q41745150-DAA4DFA5-8828-4ABC-A997-7AB8218ABADA
P2860
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Elevated liver iron concentrat ...... with β thalassemia intermedia
@ast
Elevated liver iron concentrat ...... with β thalassemia intermedia
@en
type
label
Elevated liver iron concentrat ...... with β thalassemia intermedia
@ast
Elevated liver iron concentrat ...... with β thalassemia intermedia
@en
prefLabel
Elevated liver iron concentrat ...... with β thalassemia intermedia
@ast
Elevated liver iron concentrat ...... with β thalassemia intermedia
@en
P2860
P50
P1433
P1476
Elevated liver iron concentrat ...... with β thalassemia intermedia
@en
P2093
Hani Tamim
John C Wood
P2860
P304
P356
10.3324/HAEMATOL.2011.047852
P577
2011-07-26T00:00:00Z